Trodelvy™ (sacituzumab govitecan-hziy) – New drug approval
April 22, 2020 - The FDA announced the approval of Immunomedics’ Trodelvy (sacituzumab govitecan-hziy), for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
Top